



AF/1616

PATENT

RECEIVED

DEC 14 1999

TECH CENTER 1600/2900

PATENT APPLICATION OF
Moriarty, R.M.; Penmasta, R.;
Guo, L.; Rao, M.S.;
and Mehta, R.G.

SERIAL NO.: 09/008,957

FILED: Jan. 20, 1998

TITLE: 1 α -HYDROXYVITAMIN D₅,
ITS SYNTHESIS AND USE
IN CANCER PREVENTION
AND THERAPY

Group No. 1616

Examiner: Badio

Box AF - FEE

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT TRANSMITTAL LETTER

Dear Assistant Commissioner:

Transmitted herewith is an amendment in the above-identified application, along with the amendment fee calculated below:

	Claims Remaining After <u>Amendment</u>	Highest No. Previously <u>Paid For</u>	<u>Additional Fee</u>
Total No.	19	20	-0-
Independent	6	3	<u>-117-</u>
			\$117

The U.S. Patent Office is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to Deposit Account No. 50-0358. Telephone calls concerning the accompanying amendment should be directed to Harold J. Fassnacht, telephone number 312-201-0777.

Respectfully submitted,

Harold J. Fassnacht
Harold J. Fassnacht
Reg. No. 35,507

12/14/1999 DUVONG 00000075 09008957

01 FC:202

117.00 OP

BULLWINKEL PARTNERS, LTD.
19 S. LaSalle Street - Suite 1300
Chicago, Illinois 60603-1493
Telephone: 312-201-0777

Dated: December 10, 1999



1600
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF
Moriarty, R.M.; Penmasta, R.;
Guo, L.; Rao, M.S.;
and Mehta, R.G.

SERIAL NO.: 09/008,957

FILED: Jan. 20, 1998

TITLE: 1 α -HYDROXYVITAMIN D₅,
ITS SYNTHESIS AND USE
IN CANCER PREVENTION
AND THERAPY

Group No. 1616

Examiner: Badio

RECEIVED

DEC 21 1999

TECH CENTER 1600/29

Box AF - FEE
Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION UNDER 37 CFR § 1.116
(AMENDMENT AFTER FINAL OFFICE ACTION)

RECEIVED
DEC 14 1999
TC 1700 MAIL ROOM


Sir:

In response to the Final Office Action of September 10, 1999 Applicants offer the following amendments and comments, and respectfully request reconsideration of this application.

Please amend the above-identified application as follows:

In the claims:

2. (Twice Amended) A compound of the formula [I of claim 1 wherein]:



Please enter
4/3/00
BP